{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:13:19Z","timestamp":1779315199376,"version":"3.51.4"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the safety profiles of two fluoroquinolone-containing regimens, HREL (isoniazid, rifampicin, ethambutol, levofloxacin) and HREM (isoniazid, rifampicin, ethambutol, moxifloxacin), in the treatment of drug-susceptible tuberculosis (DS-TB), focusing on adverse events (AEs) across age and gender subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were extracted from the FDA Adverse Event Reporting System (FAERS) database (2004\u20132024). Disproportionality analyses were conducted to assess AE signals for HREL and HREM. Pharmacovigilance metrics, including reporting odds ratios (RORs), proportional reporting ratios (PRRs), Bayesian confidence propagation neural networks (BCPNN), and empirical Bayesian geometric means (EBGMs), were calculated. Subgroup analyses were stratified by age (\u226560 vs. &amp;lt;60\u00a0years) and gender.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 451 HREL-related and 338 HREM-related AEs. HREL was associated with a significantly higher risk of immune reconstitution inflammatory syndrome (IRIS-TB) and drug-induced liver injury, particularly in females and patients under 60\u00a0years of age. In contrast, HREM demonstrated a higher risk of drug reaction with eosinophilia and systemic symptoms (DRESS), peripheral neuropathy, and severe hepatobiliary events such as acute liver failure. Subgroup analyses revealed that these risk profiles were influenced by age and gender. Specifically, elderly patients (\u226560\u00a0years) receiving HREM had a lower risk of IRIS-TB but a higher propensity for severe liver injury. Male patients treated with HREM showed an increased risk of neurological events, including thalamic infarction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HREM may be preferred for elderly patients (\u226560\u00a0years) due to a lower risk of immune-related events like IRIS-TB, but requires careful liver monitoring. HREL could be an option for younger patients (&amp;lt;60\u00a0years), though vigilance for hepatotoxicity and IRIS-TB is needed, especially in females. For males on HREM, increased attention to neurological AEs is recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1713170","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:05Z","timestamp":1763706545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanlang","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2174\/138920009790711823","article-title":"Metabolomics in drug intolerance","volume":"10","author":"Andreu","year":"2009","journal-title":"Curr. drug Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1063413","DOI":"10.3389\/fphar.2022.1063413","article-title":"Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters","volume":"13","author":"Annisa","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2500\/aap.2012.33.3498","article-title":"The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"33","author":"Blumenthal","year":"2012","journal-title":"Allergy Asthma Proc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/s1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin. Cutan. Med. Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"bcr0220113898","DOI":"10.1136\/bcr.02.2011.3898","article-title":"DRESS syndrome: a case report and literature review","volume":"2011","author":"Cardoso","year":"2011","journal-title":"BMJ Case Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month Rifapentine-Moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - united States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"945762","DOI":"10.3389\/fimmu.2022.945762","article-title":"Sex bias in lymphocytes: implications for autoimmune diseases","volume":"13","author":"Dodd","year":"2022","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2125.2011.03991.x","article-title":"Neurotoxic effects associated with antibiotic use: management considerations","volume":"72","author":"Grill","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/life11090950","article-title":"Hesperidin and chlorogenic acid synergistically inhibit the growth of breast cancer cells via estrogen receptor\/mitochondrial pathway","volume":"11","author":"Hsu","year":"2021","journal-title":"Life (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"693.e1","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: part I. Clinical perspectives","volume":"68","author":"Husain","year":"","journal-title":"J. Am. Acad. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"709.e1","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: part II. Management and therapeutics","volume":"68","author":"Husain","year":"","journal-title":"J. Am. Acad. Dermatol."},{"key":"B15","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/phar.1367","article-title":"Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study","volume":"34","author":"Kaye","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/15548627.2017.1339001","article-title":"ESRRA (Estrogen-related receptor \u03b1) is a key coordinator of transcriptional and post-translational activation of autophagy to promote innate host defense","volume":"14","author":"Kim","year":"2018","journal-title":"Autophagy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/jcb.21936","article-title":"Estrogenic control of mitochondrial function and biogenesis","volume":"105","author":"Klinge","year":"2008","journal-title":"J. Cell Biochem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0236109","DOI":"10.1371\/journal.pone.0236109","article-title":"The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis","volume":"15","author":"Kwon","year":"2020","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1524702","DOI":"10.3389\/fphar.2025.1524702","article-title":"Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1128\/AAC.46.5.1568-1570.2002","article-title":"Lack of interaction of fluoroquinolones with lipopolysaccharides","volume":"46","author":"Lindner","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1578406","DOI":"10.3389\/fphar.2025.1578406","article-title":"Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"ofae178","DOI":"10.1093\/ofid\/ofae178","article-title":"Experience with four-month rifapentine and moxifloxacin-based tuberculosis treatment in San Francisco","volume":"11","author":"Louie","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1517\/14656566.6.2.283","article-title":"Moxifloxacin in respiratory tract infections","volume":"6","author":"Miravitlles","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"109015","DOI":"10.1016\/j.intimp.2022.109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system","volume":"110","author":"Moore","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaneurol.2019.0887","article-title":"Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy","volume":"76","author":"Morales","year":"2019","journal-title":"JAMA Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jhep.2014.02.014","article-title":"A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease","volume":"60","author":"Nishikawa","year":"2014","journal-title":"J. Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.140.12.1537","article-title":"Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure","volume":"140","author":"Nori","year":"2004","journal-title":"Arch. Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/cid\/ciac707","article-title":"Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with human immunodeficiency virus (S31\/A5349)","volume":"76","author":"Pettit","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1473-3099(15)70008-3","article-title":"Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study","volume":"15","author":"Ravimohan","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2165\/00002018-200629110-00008","article-title":"Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use","volume":"29","author":"Sachs","year":"2006","journal-title":"Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1021\/acschemneuro.2c00200","article-title":"Stoichiometry-selective antagonism of \u03b14\u03b22 nicotinic acetylcholine receptors by fluoroquinolone antibiotics","volume":"13","author":"Sanders","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in parp inhibitors: a real-world study using fda adverse event reporting system (Faers) database","volume":"12","author":"Shu","year":"2022","journal-title":"Cancer Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"938032","DOI":"10.3389\/fcimb.2022.938032","article-title":"Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement","volume":"12","author":"Singh","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B38","unstructured":"FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection\n          \n          \n          2013"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8063","DOI":"10.4076\/1757-1626-2-8063","article-title":"Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: a case report","volume":"2","author":"Verma","year":"2009","journal-title":"Cases J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/HIV.S42328","article-title":"Immune reconstitution inflammatory syndrome in HIV-infected patients","volume":"7","author":"Walker","year":"2015","journal-title":"HIV AIDS (Auckl)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40139-013-0024-9","article-title":"Interactions between hepatitis C virus and mitochondria: impact on pathogenesis and innate immunity","volume":"1","author":"Wang","year":"2013","journal-title":"Curr. Pathobiol. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"850771","DOI":"10.3389\/fvets.2022.850771","article-title":"Effect of fluoride on cytotoxicity involved in mitochondrial dysfunction: a review of mechanism","volume":"9","author":"Wei","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"B43","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment - drug-susceptible tuberculosis treatment","year":"2022"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1164\/rccm.202501-0222LE","article-title":"The 4-Month isoniazid, rifapentine, moxifloxacin, and pyrazinamide treatment regimen for drug-susceptible pulmonary tuberculosis: a word of caution","volume":"211","author":"Wilson","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B45","volume-title":"Global tuberculosis report 2024","year":"2024"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1439115","DOI":"10.3389\/fphar.2024.1439115","article-title":"Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12890-022-02064-1","article-title":"A typical presentation of moxifloxacin-induced DRESS syndrome with pulmonary involvement: a case report and review of the literature","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Pulm. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DMSO.S348025","article-title":"Difference in gastrointestinal risk associated with use of GLP-1 receptor agonists: a real-world pharmacovigilance study","volume":"15","author":"Zhou","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12974-019-1538-9","article-title":"Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4\/NF-kB pathway","volume":"16","author":"Zusso","year":"2019","journal-title":"J. Neuroinflammation"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1713170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:09Z","timestamp":1763706549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1713170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":49,"alternative-id":["10.3389\/fphar.2025.1713170"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1713170","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1713170"}}